As innovative treatments require stringent quality control measures, drug manufacturers are increasingly embracing Quality by Design (QbD) as a pivotal strategy. In this article, Songyoung Kim, Director of CDO Downstream and Development, discusses how QbD effectively addresses potential variability and risks, thereby optimizing processes and ensuring successful development outcomes.
As innovative treatments require stringent quality control measures, drug manufacturers are increasingly embracing Quality by Design (QbD) as a pivotal strategy. In this article, Songyoung Kim, Director of CDO Downstream and Development, discusses how QbD effectively addresses potential variability and risks, thereby optimizing processes and ensuring successful development outcomes.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article